[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 subject to the liabilities]
[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 subject to the liabilities]
[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 subject to the liabilities]
[cphi_1.txt 1 13G/A]
[cphi_1.txt 1 13G/A]
[SCHEDULE 13G (Amendment No. 3)* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, par value $0.02 per share (Title of Class of Securities) 929352102 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) o Rule 13d-1(b) o Rule 13d-1(c) x Rule 13d-1(d) *The remainder of this cover page shall be filled out for a]
[cphi_2.txt 1 13G/A]
[SCHEDULE 13G (Amendment No. 3)* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, par value $0.02 per share (Title of Class of Securities) 929352102 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) o Rule 13d-1(b) o Rule 13d-1(c) x Rule 13d-1(d) *The remainder of this cover page shall be filled out for a]
[cphi_2.txt 1 13G/A]
[Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement Press Release: Sinovac Biotech Co., Ltd. – Tue, Jan 24, 2012 4:05 PM EST BEIJING, Jan. 24, 2012 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA - News), a leading provider of vaccines in China, today announced that it received a letter dated January 18, 2012 from The Nasdaq Stock Market. Based] [Sinovac Commences the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease Press Release: Sinovac Biotech Ltd. – Tue, Jan 10, 2012 8:00 AM EST BEIJING , Jan. 10, 2012 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA - News), a leading provider of biopharmaceutical products in China , announced today that the phase III clinical] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F ¨ SINOVAC BIOTECH LTD. 6-K 1 v301323_6k.htm FORM 6-K]
